Amarin Corporation plc is a commercial-stage pharmaceutical company focused on developing therapies, especially based on omega-3 fatty acid for treating cardiovascular diseases. The company's sole marketed drug, Vascepa (icosapent ethyl) is approved in the United States as an adjunct to diet for treating severe hypertriglyceridemia or elevated triglyceride levels. The FDA approved Vascepa to reduce cardiovascular risk in patients with persistent elevated triglycerides on statin therapy for LDL-C. The drug received approval for both indications in Europe under the tradename of Vazkepa. It has initiated various promotional activities and direct-to-consumer programs as well as expanded its salesforce to support promotion of Vascepa's expanded label. A generic version of Vascepa has been launched for elevated TG levels....
+See More2022-10-15 09:34:00 Saturday ET
Internal capital markets and financial constraints Duchin (JF 2010) empirically finds that multidivisional firms with robust internal capital markets ret
2023-12-03 11:33:00 Sunday ET
Macro innovations and asset alphas show significant mutual causation. April 2023 This brief article draws from the recent research publicati
2017-09-19 05:34:00 Tuesday ET
Facebook, Twitter, and Google executives head before the Senate Judiciary Committee to explain the scope of Russian interference in the U.S. presidential el
2017-08-31 09:36:00 Thursday ET
The Trump administration has initiated a new investigation into China's abuse of American intellectual property under Section 301 of the Trade Act of 19
2018-10-13 10:44:00 Saturday ET
Dow Jones tumbles 3% or 831 points while NASDAQ tanks 4%, and this negative investor sentiment rips through most European and Asian stock markets in early-O
2019-02-05 10:32:00 Tuesday ET
President Trump remains optimistic about the Sino-American trade war resolution of both trade deficit eradication and tech transfer enforcement. Trump now s